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The impact of nutrition in urogenital cancers
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A b s t r a c t
Prostate, bladder and kidney cancers remain the most common cancers 
of the urinary tract. Despite improved primary prevention, detection and 
treatment, the incidence of age-related cancers of the urinary tract is likely 
to rise as a  result of global population ageing. An association of diet with 
prostate, bladder and kidney carcinogenesis is plausible since the majority 
of metabolites, including carcinogens, are excreted through the urinary tract. 
Moreover, large regional differences in incidence rates of urologic tumours 
exist throughout the world. These rates change when people relocate to 
different geographic areas, which is suggestive of a  strong environmental 
influence. As a  result of these observations, numerous studies have been 
conducted to assess the effects of diet and nutritional status in kidney, blad-
der and prostate carcinogenesis. Here, we review the literature assessing 
the effect of diet and nutritional status on urological cancer risk, which has 
attracted the most interest.
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Introduction
Kidney, bladder and prostate cancers remain the most common can-
cers of the urinary tract. In recent years, there have been substantial 
changes in urologic cancer related mortality in Europe as well as in North 
America [1, 2]. This has been a result of therapeutic improvements for 
prostatic cancer, decreased exposure to tobacco smoking and occupa-
tional carcinogens for bladder and possibly kidney cancers [3–8].
Despite improved primary prevention, early detection and treatment, 
the incidence of age-related cancers of the urinary tract is likely to rise as 
a result of global population ageing. As both modifiable and non-modi-
fiable risk factors are believed to be involved in carcinogenesis, and the 
multistage process of initiation, promotion and progression of cancer 
requires many years, it therefore provides an opportunity to employ pre-
ventive measures. 
Diet and nutritional factors are believed to act as pro- and antitu-
mor risk modifiers across the entire complicated process of urogenital 
tumourigenesis [9]. Consequently, malnutrition, which is a  pathologic 
state of varying severity with clinical features caused by deficiency, ex-
cess, or imbalance of essential nutrients, may also play a  role [10]. So 
far, however, no specific diet has been shown to prevent or eradicate 
urinary tract cancers. This can likely be explained by the complexity of 
Tomasz Golabek, Jan Powroźnik, Piotr Chłosta, Jakub Dobruch, Andrzej Borówka
412 Arch Med Sci 2, April / 2015
the disease, where both genotypic and pheno-
typic alterations occur as a  result of generalised 
carcinogen exposure and clonal proliferation of 
mutated cells. On the other hand, there is often 
a lack of high quality long-term randomized con-
trolled studies that could observe remote effects 
of diet modification on cancer development and 
progression. Dietary studies are commonly limited 
in their conclusions because of heterogeneity of 
the study population, variations in lifestyles and 
the complexity of diet, with different components 
of the food exerting potential chemopreventive 
effects. Nevertheless, large regional differences in 
incidence rates of urologic tumours exist through-
out the world. Moreover, these rates change when 
men and women relocate to different geographic 
areas, which is suggestive of a strong environmen-
tal influence. As a  result of these observations, 
many cell culture, animal and human studies have 
been conducted to assess the effects of diet and 
nutritional status in kidney, bladder and prostate 
carcinogeneses. 
Here, we review the literature assessing the 
effect of diet and nutritional status on urological 
cancer risk, which has attracted the most interest.
Obesity
The hypothesis of obesity and fatty diet in-
volvement in prostate and renal carcinogenesis 
was made after having analysed differences in the 
overall prevalence of these two cancers in people 
of various ethnic origins and, also, men who mi-
grated to the USA from countries of low baseline 
incidence of prostate and renal cancers [11–14]. 
Obesity is the strongest environmental risk fac-
tor in the aetiology of prostate cancer. Multiple 
studies have also shown its positive correlation 
with more aggressive tumours, as well as a higher 
likelihood of tumour recurrence following surgery 
or radiation therapy [15–19]. The study, which an-
alysed the Cancer Prevention Study derived data 
on 10 258 men who underwent prostate biopsy, 
revealed that obesity (defined as body mass index 
(BMI) ≥ 30 kg/m2) was associated with an 18% 
decreased risk of developing a  low-grade cancer 
(Gleason < 7) and a 29% increased risk of devel-
oping high-grade adenocarcinoma. Patients who 
were obese and had a  Gleason sum of 8 to 10 
were at a 78% increased risk of malignant trans-
formation [20]. Similarly, the Cancer Prevention 
Study II results confirmed the inverse association 
between BMI and risk of low-grade cancer, as 
well as a positive correlation between raised BMI 
and risk of high-grade, metastatic or fatal cancer 
[21]. This study also showed that men who lost 
> 5 kg of weight during 10 years of follow-up re-
duced their risk of diagnosis with non-metastatic 
high-grade prostate cancer. This was until Calle 
et al. published their breakthrough results which 
showed that prostate cancer and renal cell carci-
noma (RCC) related mortality was proportionally 
greater in subjects with higher BMI. The same 
relationship was noted in patients who suffered 
from bladder cancer [22].
In contrast, the association between BMI and 
the risk of developing urothelial bladder cancer 
(UBC) is poorly understood and still remains con-
troversial. In the study conducted by Koebnick 
et al., a  cohort of 47  1760 people was prospec-
tively followed from 1995 to 2003. A  diagnosis 
of bladder cancer was documented in 1719 cas-
es where, compared with normal weight, obesity 
carried a  28% increased risk of developing UBC 
[23]. Multivariate analysis showed that in higher 
BMI subgroups a  further increase in the relative 
risk of bladder cancer was not as marked. For BMI 
18.5–24.9, 25.0–29.9, 30.0–34.9 and ≥ 35 kg/m² 
relative risk of bladder cancer was respectively 1.0, 
1.15, 1.22 and 1.28 (95% confidence interval (CI): 
1.02–1.61; p = 0.028). This contrasts, however, 
with the study results reported by Holick, together 
with a Harvard University group, who prospective-
ly analysed data from two cohorts of the Health 
Professionals Follow-Up Study and the Nurses’ 
Health Study. This study, which included 121 700 
women and 51 529 men, did not show any rela-
tionship between BMI and risk of bladder cancer 
[24]. Of added interest is the evidence suggesting 
that TP53 mutation frequency (which correlates 
well with UBC initiation and progression) was low-
er in obese and overweight patients as compared 
to normal weight patients (25%, 44.8% and 68.4% 
respectively (p < 0.05)) [25]. Hence, considering all 
available evidence, one cannot be certain if the as-
sociation between obesity and an increased risk 
of urothelial carcinoma of the bladder is true. 
In contrast, the relationship between BMI and 
the risk of renal cell cancer, with its clear cell 
variant in particular, is well known. Earlier stud-
ies reported a  stronger relation between obesity 
and RCC in women [26]. A recent review, however, 
found a positive relation between BMI and RCC, 
which was equally strong for both sexes [14]. In 
a  quantitative summary analysis, Bergström et 
al. estimated that the relative risk for renal cell 
cancer was 1.07 (95% CI: 1.05–1.09) per unit of 
increase in BMI, irrespective of gender. This cor-
responds with a  7% increased risk of RCC with 
each 3 kg weight gain [27]. Over the past decade 
there have been several research projects focusing 
on the incidence of RCC and the age of onset of 
obesity. The majority of them reported inconclu-
sive results, except for one prospective study from 
2008. The authors analysed a cohort of 32 0618 
men and women and not only proved an apparent 
link between BMI and RCC, but also that weight 
gain in early (age 18–35) and mid- (age 35–50) 
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adulthood is strongly associated with RCC risk. 
This correlation, however, was not observed when 
weight gain occurred after 50 years of age [28]. 
The mechanisms involved in increased risk of 
RCC in overweight and obese patients are most 
likely related to excess production of insulin-like 
growth factor (IGF-1), steroid hormones and some 
specific type proteins [29]. Lipid peroxidation also 
seems to play an important role [30].
Dietary fat and lipids 
A possible link between fatty diet and prostate 
cancer attracted researchers’ attention following 
a  report of a  study from 31 countries, which re-
vealed a  close correlation between the average 
per capita fat intake and increased prostate can-
cer mortality in Western Europe and the USA, as 
opposed to countries with proportionally low fat 
consumption [31, 32]. Interestingly, introducing 
a westernized diet to Japanese men, who normally 
eat low fat foods, led to increased prostate cancer 
incidence [33]. A positive association of prostate 
cancer risk and total fat intake seems to depend 
on the fat type and its compounds. Whittemore 
et al. analysed the relation between diet, physical 
activity and body size in white, black and Asian 
populations. They found that the ingested amount 
of saturated fats in the diet was the only pros-
tate cancer risk factor present [34]. Similar results 
come from the study by Giovannucci et al., who re-
ported that men who eat large amounts of animal 
fat in their diet, particularly α-linolenic acid from 
red meat, are not only at a greater risk of devel-
oping prostate cancer in general but also tend to 
develop more advanced tumour [35]. It seems that 
the relationship between the amount of ingested 
animal and saturated fat correlates well with the 
risk of prostate cancer. A  clear cause and effect 
relationship, however, has not yet been shown. 
One of the proposed mechanisms underlying the 
role of dietary fat in the initiation and progression 
of prostate cancer explains it by an alteration in 
androgen levels, damage caused by lipid-derived 
free radicals as well as proinflammatory cytokines 
(leukotrienes and prostaglandins), which may ex-
hibit pro-carcinogenic and cancer growth promot-
ing properties [36–38]. Moreover, a  low-fat diet 
seems to positively correlate with low IGF-1 serum 
levels and also with slower growth of human pros-
tate cancer cells [39].
The evidence, so far, confirming an association 
between the amount and type of dietary fat and 
the risk of bladder cancer, is rather scarce and 
equivocal [40]. This is mainly because of a paucity 
of epidemiological data, as well as being due to 
the different types of lipids being reported on, in 
relation to this topic [41, 42]. Both Swedish and 
Spanish studies have shown a direct link between 
dietary fat intake and the risk of urothelial carci-
noma of the bladder [41, 43]. The estimated can-
cer risk was between 1.4 and 1.7. In the Spanish 
study UBC was predominantly associated with 
saturated fats. This association, however, could 
not be found with regard to the mono- and polyun-
saturated fats. Contrasting results were obtained 
from the cohort analysis of Japanese men living in 
Hawaii, which did not confirm the link between 
dietary fat content or the total calorific intake and 
bladder cancer [44]. Nonetheless, a meta-analysis 
of 36 epidemiologic studies, which investigat-
ed the impact of six dietary variables – retinol, 
b-carotene, fruits, vegetables, meat, and fat – on 
the risk of developing bladder cancer, did confirm 
the link between ingested fat and bladder cancer 
(relative risk (RR) = 1.37; 95% CI: 1.16–1.62), but 
failed to show its association with a high dietary 
meat intake (RR = 1.08; 95% CI: 0.82–1.42) [45].
The protective role of plant oils rich in unsatu-
rated fatty acids seems therefore compelling from 
the bladder cancer chemoprevention perspective. 
In their study Radosavljevic et al. found a protec-
tive role for sunflower oil against the develop-
ment of bladder cancer, in people consuming large 
amounts of animal fats [42]. Similarly, olive oil was 
reported to harbour the same protective proper-
ties in a study from 2011 [46].
The association between RCC and dietary fat 
content has also been looked at for the past few 
decades. The evidence in this field, however, is gen-
erally limited, mainly focusing on meat consump-
tion, and is, overall, inconclusive [47]. In a  large 
multicentre study which involved 18 countries, 
Wynder et al. found a positive correlation between 
RCC related mortality and per capita animal fat and 
protein consumption [48]. However, the latest sys-
tematic review of 12 published case-control stud-
ies, 3 cohort studies and 1 analysis of 13 pooled 
international cohort studies revealed no relation 
between red meat consumption and RCC [49].
For the past few decades a lot of research has 
been dedicated towards recognising the ben-
eficial properties of omega-3 and carcinogenic 
properties of omega-6 polyunsaturated fatty ac-
ids. A study by Ritch et al., which investigated 148 
Jamaican men (Jamaica has the world’s highest 
incidence of prostate cancer, and Jamaican food is 
rich in omega-6 fatty acids) found positive correla-
tions between omega-6 fatty acids and Gleason 
score as well as the omega-3/omega-6 fatty acid 
ratio and tumour volume [50]. These results are 
suggestive of stimulatory effects of omega-6 fatty 
acids, and inhibitory effects of omega-3 fatty ac-
ids in prostate carcinogenesis.
An interesting report was published by a British 
group in which they described the protective prop-
erties of fish oils in renal cell cancer pathogenesis. 
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The authors demonstrated that the docosahexae-
noic acid (DHA) derived from fish oil can increase 
levels of tissue inhibitors of metalloproteinase-1 
(TIMP-1) in the renal cancer clear cell line and it 
also reduces cancer invasion through the base-
ment membrane [51].
Cholesterol and statins
Preclinical studies suggest that statins may 
play a role in cancer biology and may therefore be 
used in chemoprevention. Studies in vitro proved 
that lovastatin as well as simvastatin can stop 
both normal and neoplastic cell growth in mice, 
hamsters and humans by holding the cell cycle in 
G1 phase and enhancing apoptosis [52, 53]. These 
drugs, moreover, have anti-inflammatory, anti-
angiogenic and antiproliferative properties. They 
also prevent migration, adhesion and cell invasion 
[54]. The most recent meta-analysis, which criti-
cally reviewed 27 high quality studies and pooled 
a total of 56 847 prostate cancer patients, demon-
strated a  7% decrease in the overall cancer risk 
in men taking statins as compared to men not 
taking them. Furthermore, the statin treatment 
group had a  lower risk of more advanced malig-
nancy [55].
One interesting study in rats investigated the 
chemopreventive efficacy of atorvastatin against 
bladder cancer [56]. In four study groups ani-
mals received: 1. placebo, 2. statin, 3. carcinogen 
(N-butyl-N-(4-hydroxybutyl)nitrosamine) or 4. car-
cinogen and statin for 8 weeks. Bladder cancer 
risk was estimated 12 weeks later and a statisti-
cally significant cancer risk reduction was found 
in the group receiving carcinogen together with 
atorvastatin, as compared to rats receiving the 
carcinogen alone (12.5% and 68% respectively). 
This effect was explained as being mainly due to 
the antiproliferative, antioxidant and anti-inflam-
matory properties of statins. In humans, however, 
clear-cut evidence to support the protective prop-
erties of statins against bladder cancer is lacking 
[57]. The latest meta-analysis in this field reported 
that statins have some minor protective proper-
ties in UBC pathogenesis [58].
A similar effect of statins was also found in rela-
tion to renal cancer [59]. Not all studies, however, 
confirm this observation. An observational-clinical 
study from the USA provided evidence consistent 
with the hypothesis that statin use does not have 
a substantial effect on cancer risk [60]. In addition, 
the most recent meta-analysis studying the effect 
of statins in renal cell cancer did not find any sta-
tistically significant correlation [58].
The cumulative evidence from analytical epi-
demiologic studies supports the hypothesis that 
cholesterol lowering with statins is beneficial for 
both prostate cancer prevention and for clinically 
important advanced adenocarcinoma. However, 
the role of prostate-specific antigen (PSA) screen-
ing and underlying biological mechanisms for the 
observed association needs to be more thorough-
ly investigated. Despite preclinical data attribut-
ing statins with chemopreventive properties in 
bladder cancer, it is not quite certain whether its 
anticarcinogenic properties can be definitely rec-
ognised and likely requires further investigation. 
Further research is needed to address the role of 
cholesterol-lowering medications in renal cancer.
Diabetes
Diets high in glycaemic index or glycaemic load 
have been hypothesised to increase the risks of 
certain cancers by increasing blood glucose or in-
sulin concentrations. Epidemiologic data suggest 
that individuals with type 2 diabetes are at an in-
creased risk of developing several types of cancer 
including pancreas, liver, breast, colorectal, and 
female reproductive organs [61].
Similarly, a series of recent studies and meta- 
analyses confirmed that the risk for kidney and 
bladder malignancies is elevated in diabetic pa-
tients [62–64].
The increased incidence and mortality for kid-
ney cancer have been attributed to hyperinsuli-
naemia, obesity and hypertension, as well as the 
frequent kidney diseases occurring in diabetic pa-
tients [65, 66]. A  modest increase in the risk of 
bladder cancer in patients with diabetes mellitus 
is most likely related to hyperinsulinaemia and the 
increased frequency of urinary tract infections.
Interestingly, men with diabetes have been 
found to be less likely to develop prostate cancer 
[67]. A 2006 meta-analysis of 19 studies involving 
a total population of one million including 20 373 
prostate cancer cases showed a  16% decreased 
risk of developing prostate cancer. The latest 
pooled analysis of 45 studies indicated that pa-
tients with type 2 diabetes were associated with 
an estimated reduction of 14% in the risk of de-
veloping prostate cancer, as compared with those 
without diabetes [68].
This association has been attributed to the 
change of insulin and testosterone levels in dia-
betic patients. Initially, many type 2 diabetic men 
are hyperinsulinaemic, but as the disease pro-
gresses, the levels of insulin may decline [67]. As 
growth of both normal and cancerous prostate 
cells is positively associated with raised levels of 
insulin, a  decreased level of this hormone may 
have a  growth inhibitory effect on these cells 
[69]. Several other factors, including altered leptin 
concentrations, the use of medications such as 
statins and metformin, and changes in diet and 
lifestyle in order to control diabetes, have also 
been implicated in biological mechanisms behind 
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the decreased risk of prostate cancer in patients 
with diabetes mellitus [70, 71].
Although diabetic patients have a reduced risk 
of prostate cancer, once an insulin-resistant, over-
weight man has been diagnosed with prostate 
cancer, his likelihood of dying from the disease is 
four times higher than a  non-diabetic individual 
with BMI < 25 kg/m² [72].
With the present evidence, one cannot accu-
rately define the general and the specific organ 
cancer risks in any individual diabetic patient. 
Future studies are needed to elucidate potential 
pathophysiological links between diabetes and 
urinary tract cancers.
Nutritional deficiency
The prevalence of nutritional deficiency in on-
cology patients is higher compared to the back-
ground of a healthy population. This is due to the 
cancer-specific characteristics, as well as treat-
ment processes, and it is suspected to be asso-
ciated with approximately 20–50% of deaths in 
cancer patients [73].
Both prospective and retrospective studies, in 
patients diagnosed with non-urologic malignancy, 
demonstrated that patient’s pre- as well as post-
operative nutritional status correlate well with the 
risk of postoperative complications and mortali-
ty [74–77]. There are also reports suggesting that 
some elements of the nutrition, such as hypoal-
buminaemia, weight loss, anorexia, and malaise, 
can independently affect survival in renal cancer 
patients [78, 79]. One retrospective study anal-
ysed 369 patients diagnosed with renal cancer, 
who underwent radical or partial nephrectomy, 
and it showed that preoperative malnourishment 
was associated with a 41.5% 3-year mortality rate 
compared with a 19.6% mortality rate in patients 
with normal preoperative weight [80]. Similarly, 
several reports suggest that hypoalbuminaemia, 
preoperative loss of weight and fall in BMI are pow-
erful predictors of 90-day perioperative mortality 
rate, overall survival in patients undergoing radi-
cal cystectomy, as well as the risk of perioperative 
complications [81–84]. The latest and the largest 
retrospective study analysed how preoperative nu-
tritional status can influence survival rate in 538 
surgically treated patients who were diagnosed 
with bladder cancer [83]. The results of this study 
indicated an inverse association of preoperative 
nutritional deficiency, assessed clinically and bio-
chemically, and perioperative mortality in patients 
undergoing radical cystectomy for bladder cancer. 
The 90-day mortality rate in the malnourished pa-
tient group was greater than in the control group 
of normal weight patients (16.5% vs. 5.1% respec-
tively). This difference was even more significant 
when the study period was extended to 3 years 
(55.5% vs. 32.4% respectively). Both studies, how-
ever, had a few major limitations related namely 
to their retrospective study design. As the authors 
applied the clinical definition of nutritional defi-
ciency based solely on symptoms, one could never 
be sure whether they were caused by the paraneo-
plastic syndrome or malnourishment independent 
of the cancer. This posed a significant challenge to 
answering the question of whether preoperative 
nutrition deficiency, which is unrelated to can-
cer, can further predict postoperative survival, or 
postoperative survival is simply a derivative of the 
preoperative cancer burden. In addition, there was 
no postoperative nutritional status assessment in 
both studies. It is likely, therefore, that postopera-
tive survival in patients diagnosed with renal and 
bladder cancers has more to do with the postop-
erative than the preoperative nutritional status. Fi-
nally, a patient’s general condition, which can also 
serve as a marker of future survival, has never pre-
viously been evaluated in those cancer patients.
So far there are no prospective data provid-
ing better evidence of whether nutritional status 
could be related to the risk of postoperative com-
plications and mortality in renal as well as bladder 
cancer patients.
Discussion
The evidence from epidemiologic studies link-
ing diet and nutritional status with prostate, 
bladder and kidney cancers is still limited and in-
consistent. Although the amount of the research 
is overwhelming, most of the published studies 
are not of the highest quality and have a  short 
follow-up. This is due to the difficulties in obtain-
ing homogeneity of the study population and the 
number and quality of foods or nutrients that 
would allow for randomised controlled studies 
to be performed. However, despite limitations 
and inconsistencies which make it difficult to 
reach explicit conclusions in most of the cases 
investigating the correlation between diet and 
urinary tract tumours, the cumulative evidence 
is compelling for a  strong association of obesi-
ty with the risk of prostate and kidney cancers. 
However, several aspects of being overweight or 
obese, including weight development during life-
time, weight cycling, body fat distribution and its 
potential mechanisms of action, require further 
investigation.
Findings from a study in the transgenic mouse 
model suggest that the ability of calorific restric-
tion to inhibit or delay prostate cancer incidence 
and progression is mediated in part by changes in 
energy balance, body mass, and/or body composi-
tion rather than calorie intake per se. This implies 
that the risk of tumourigenesis depends on excess 
caloric retention, rather than consumption [85]. 
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However, it is not known whether these results 
can be expected in humans.
Interestingly, cardiovascular disease, which is 
a  leading cause of prostate cancer mortality, is 
also related to BMI [86–91]. Although not enough 
evidence exists to warrant recommending partic-
ular dietary changes, in order to reduce the risk 
of urinary tract tumours, data have shown that 
a diet consisting mainly of vegetables, fruits and 
fish, combined with adequate calorific intake and 
exercise, is effective in reducing the risk of obesity 
and diabetes as well as death from cardiovascu-
lar disease. Therefore, any clinical counselling or 
public health message on nutrition and prevention 
of the aforementioned cancers should stress the 
importance of dietary modifications that reduce 
dietary fat intake along with increased regular 
physical activity. The role of other dietary compo-
nents on the process of urinary tract tumour car-
cinogenesis remains open until strong evidence is 
obtained.
In summary, obesity is the most significant di-
et-related risk factor for prostate and renal can-
cers. However, as the complexity of the disease 
cannot be explained by a single element, it is likely 
that no specific diet will completely prevent the 
development of a  neoplasm or alter the growth 
of an existing tumour. Thus, primary prevention 
should aim to reduce an individual’s exposure to 
all known modifiable risk factors involved in uri-
nary tract carcinogenesis, including both dietary 
and non-dietary ones. Implementation of lifestyle 
changes for the obese or smokers, through weight 
control and smoking cessation programmes, 
needs to be encouraged and supported. Further 
prospective trials, focused on at-risk populations 
and malnutrition, are needed.
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